english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Covid-19: Follow Prescrire's independent, evidence-based analysis of the pandemic

 COVID-19  Prescrire's editors are publishing an ongoing series of articles featuring independent analysis of developments related to the covid-19 pandemic. Useful and practical information, to help health professionals gain a clear and balanced view.
1 December 2022

Dapivirine vaginal ring in the prevention of HIV

 Marketing Authorisations  Fragile data from a single clinical trial suggest that the dapivirine vaginal ring has at best partial efficacy in the prevention of HIV infection, with a considerable margin of uncertainty.
Full article (4 pages) available for download by subscribers.
1 December 2022

Europe and medicines

 Editorial  The European Commission is due to propose changes to European pharmaceutical legislation in early 2023, in what has been presented as a major revision. No doubt the industry's lobby groups will attempt to shape the legislation in their favour. But civil society organisations will also have their say.
1 December 2022

Opioids: endocrine disruptors

 Adverse Effects  Data from clinical trials, cohort studies and other sources show that opioids also have several endocrine effects, usually in the form of a hormone insufficiency, by acting on the hypothalamic-pituitary axis.
Full article (3 pages) available for download by subscribers.
1 December 2022

Impending changes to European pharmaceutical regulations: part 1

 ADVANCING HEALTHCARE POLICY  In 2020, the European Commission announced its new "Pharmaceutical Strategy for Europe" for the coming years. The new legislation is due to be published in 2023.
Full article (3 pages) available for free download.
1 December 2022

Nivolumab (Opdivo°) as adjuvant treatment for certain oesophageal cancers

 Marketing Authorisations  No proven increase in survival, as of mid-2022, in a double-blind randomised placebo-controlled trial in 794 patients. Longer time before relapse, but with adverse effects that are sometimes serious.
Full article (1 page) available for download by subscribers.
1 December 2022

Bivalent mRNA covid-19 vaccines that also target the Omicron variant: more antibodies

 Marketing Authorisations  Four bivalent messenger RNA (mRNA) vaccines, based on the first Sars-CoV-2 strain isolated and a strain of the Omicron variant of this virus, have been authorised in the European Union. How do Prescrire's editors rate these vaccines?
Full article (2 pages) available for download by subscribers.
1 December 2022

Risdiplam (Evrysdi°) in spinal muscular atrophy. Continue the evaluation

FEATURED REVIEW Risdiplam has been authorised in the European Union for use in patients aged 2 months or older with spinal muscular atrophy. How do Prescrire's editors rate this drug in this situation?
Full review (3 pages) available for download by subscribers.
1 November 2022

A change of paradigm

 Editorial  It is time to extricate ourselves from the paradigm in which drugs are the mainstay of our response to health problems, and to embrace one in which they are just one option rather than an automatic reflex.
1 November 2022

Liraglutide (Saxenda°) in obesity in adolescents: not acceptable

Liraglutide is authorised for use in patients with type 2 diabetes and in obese adults. Its marketing authorisation has now been extended to include obese adolescents.
1 November 2022

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90